Bangladesh has made significant progress in all aspects, if hepatitis B management in the recent years. On one hand, we have local
generics of most approved antivirals against hepatitis B, including pegylated interferon, which has brought down treatment cost significantly.
On the other extreme, significant progress has also been made in the research arena and good quality papers on hepatitis B from Bangladesh
are now being published regularly in impact factor journals. Several clinical trials have already been completed, while others are ongoing,
which is testimony to the very promising side of hepatology in Bangladesh as a whole.